Abobotulinumtoxina is under clinical development by Ipsen and currently in Phase III for Migraine. According to GlobalData, Phase III drugs for Migraine have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abobotulinumtoxina’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Abobotulinumtoxina overview

Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure) is a neuromuscular blocking agent. It is formulated as lyophilized powder for solution, solution for intramuscular and subcutaneous route of administration. Dysport is indicated for the treatment of cervical dystonia in adults for reducing the severity of abnormal head position and neck pain in both toxin-naive and previously treated patients. It is also used for blepharospasm, spasmodic torticollis, hemifacial spasm, upper limb spasticity in adult patients, to decrease the severity of increased muscle tone in the elbow, wrist, and finger flexors, pediatric lower limb (PLL) spasticity in children two years of age and older, for the symptomatic treatment of focal spasticity affecting the lower limbs in adults.Dysport is also indicated for the symptomatic treatment of focal spasticity of upper limbs in pediatric cerebral palsy patients, two years of age and older. Dysport is indicated for the treatment of focal sapasticity affecting the upper and lower limbs in patients 2 years of age and older.

The drug candidate is under development for the treatment for migraine.

The drug candidate was under development for the treatment of pediatric lower limb spasticity in EU, oromandibular dystonia, abdominal or thoracic chronic scar pain and pain associated with hallux valgus (Bunion). It is administered intramuscular and intradermal through. It was also under development for chronic low back pain, myofascial pain syndromes, chronic plantar fasciitis, lateral epicondylitis(tennis elbow), degenerative coxarthrosis (osteoarthritis of the hip joint), anal fissure and urinary incontinence in subjects with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS). It was under development for the treatment of vulvodynia.

Ipsen overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Paris, France.

For a complete picture of Abobotulinumtoxina’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.